Earnings ·
Fractyl Health reported second quarter 2026 financial results and provided clinical updates
GUTSFractyl Health, Inc.
Fractyl Health reported second quarter 2026 financial results and provided clinical updates. The company posted a net loss of $25.5 million, compared to $27.9 million in the prior year period, driven by reduced R&D expenses of $13.8 million against $21.2 million previously. Cash and cash equivalents stood at approximately $47.1 million as of June 30, 2026, with management projecting a cash runway into early 2027. Clinically, one-year data from the REMAIN-1 Midpoint Cohort showed Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% for sham controls. Topline six-month randomized data from the REMain-1 Pivotal Cohort is expected in early Q4 2026, potentially paving the way for an FDA De Novo submission later that quarter. Fractyl Health operates in the biotechnology and medical device industry, developing procedural therapies and gene treatments for obesity and type 2 diabetes.